and unexpected results, which may, in some examples, include one or both of delayed peak effect and/or extended duration of response.

[0006a] In one aspect of the present disclosure, there is provided a use of a composition comprising a large agent having a molecular weight of 100,000 Da or greater in the manufacture of a medicament for treating a disease, disorder, or condition that is treatable by the large agent in a subject, wherein the medicament is to be administered to a site on skin of the subject in combination with microneedle skin conditioning (MSC), wherein the subject is to be treated according to a dosing regimen in which at least two successive doses of the medicament in combination with MSC are separated from one another by a time period of at least one month.

[0006b] In a further aspect of the present disclosure, there is provided a non-therapeutic method comprising a step of:

administering a plurality of doses of a composition that delivers a large agent having a molecular weight of 100,000 Da or greater to a site on skin of the subject in combination with microneedle skin conditioning (MSC) according to a dosing regimen in which at least two successive doses are separated from one another by a time period of at least one month.

Brief Description of the Drawing

[0007] Figure 1: Figure 1 presents a bar graph comparing responder rates observed with provided technologies as compared with an approved injectable botulinum toxin therapy, and

We claim:

1. Use of a composition comprising a large agent having a molecular weight of 100,000 Da or greater in the manufacture of a medicament for treating a disease, disorder, or condition that is treatable by the large agent in a subject, wherein the medicament is to be administered to a site on skin of the subject in combination with microneedle skin conditioning (MSC), wherein the subject is to be treated according to a dosing regimen in which at least two successive doses of the medicament in combination with MSC are separated from one another by a time period of at least one month.

2. The use of claim 1, wherein the time period is at least two months.

3. The use of claim 1, wherein the time period is at least four months.

4. The use of claim 1, wherein the time period is at least six months.

5. The use of claim 1, wherein the time period is at least eight months.

6. The use of claim 1, wherein the time period is at least ten months.

7. The use of claim 1, wherein the time period is at least twelve months.

8. The use of claim 1, wherein the dosing regimen comprises at least three doses of the medicament, separated by at least first and second time periods, wherein the average time period is at least one month.

9. The use of claim 8, wherein the average time period is at least two months.

10. The use of claim 8, wherein the average time period is at least four months.

11. The use of claim 8, wherein the average time period is at least six months.

12. The use of claim 8, wherein the average time period is at least eight months.

13. The use of claim 8, wherein the average time period is at least ten months.

14. The use of claim 8, wherein the average time period is at least twelve months.

15. The use of claim 8, wherein each of the time periods is the same.

16. The use of claim 15, wherein each of the time periods is at least one month.

17. The use of claim 15, wherein each of the time periods is at least two months.

18. The use of claim 15, wherein each of the time periods is at least four months.

19. The use of claim 15, wherein each of the time periods is at least six months.

20. The use of claim 15, wherein each of the time periods is at least eight months.

21. The use of claim 15, wherein each of the time periods is at least ten months.

22. The use of claim 15, wherein each of the time periods is at least twelve months.

23. The use of any one of the preceding claims, wherein the treatment comprises topically applying the composition to the site.

24. The use of any one of the preceding claims, wherein the composition comprises a nanoemulsion.

25. The use any one of the preceding claims, wherein the composition comprises a macroemulsion.

26. The use of any one of the preceding claims, wherein a penetration enhancing agent is to be further administered to the subject.

27. The use of claim 26, wherein the penetration enhancing agent is selected from carrier peptides and co-peptides.

28. The use of any one of claims 26-27, wherein the penetration enhancing agent is selected from a cationic peptide and a positively charged carrier with the sequence RKKRRQRRRG-$(K)_{15}$-GRKKRRQRRR.

29. The use of any one of the preceding claims, wherein the subject is to be treated with the medicament, and wherein the MSC is to be performed on the subject prior to the treatment with the medicament.

30. The use of any one of the preceding claims, wherein the subject is to be treated with the medicament, and wherein the MSC is to be performed on the subject after the treatment with the medicament.

31. The use of any one of the preceding claims, wherein the subject is to be treated with the medicament, and wherein the MSC is to be performed on the subject while being treated with the medicament.

32. The use of any one of the preceding claims, wherein the large agent is a botulinum toxin.

33. The use of claim 32, wherein the treatment is further in combination with a cosmetic or therapeutic agent.

34. The use of claim 33, wherein the cosmetic or therapeutic agent is selected from the group consisting of anesthetics, collagen, fillers, retinoids, silicone, steroids, and combinations thereof.

35. The use of claim 34, wherein the cosmetic or therapeutic agent is selected from the group consisting of hydrocortisone, retin A, lidocaine, and combinations thereof.

36. The use of any one of the preceding claims, wherein the large agent is an antibody agent.

37. The use of claim 36, wherein the antibody agent is selected from the group consisting of an anti-TNFα antibody, an anti-CD2 antibody, an anti-CD4 antibody, an anti-IL-12 antibody, an anti-IL-17 antibody, an anti-IL-22 antibody, and an anti-IL-23 antibody.

38. The use of any one of claims 36-37, wherein the antibody agent is selected from the group consisting of an antibody having epitope binding elements found in one or more of infliximab, adalimumab, golimumab, etanercept, etanercept-szzs, certolizumab pegol,

siplizumab, zanolimumab, briakinumab, secukinumab, brodalumab, fezakinumab, ustekinumab and/or guselkumab.

39. The use of any one of claims 36-38, wherein the treatment is further in combination with a cosmetic or therapeutic agent.

40. The use of any one of claims 36-39, a penetration enhancing agent is to be further administered to the subject.

41. The use of claim 40, wherein the penetration enhancing agent is selected from co-peptides and carrier peptides.

42. The use of any one of the preceding claims, wherein the MSC is accomplished with a device comprising at least one microneedle (MN).

43. The use of claim 42, wherein the device comprises a plurality of MN.

44. The use of claim 42 or 43, wherein the device is a patch, a roller, a stamp, or a pen.

45. The use of any one of the preceding claims, wherein the site is a skin surface overlying a muscle or muscle group.

46. The use of any one of the preceding claims, wherein the site is a skin surface that contains sweat glands.

47. The use of any one of the preceding claims, wherein the site is a skin surface that contains sebaceous glands.

48. The use of any one of the preceding claims, wherein the site is a skin surface that contains hair follicles.

49. The use of any one of claims 42-47, wherein the MN have a length sufficient to project through the stratum corneum of the skin.

50. The use of any one of claims 42-49, wherein the MN have a length insufficient to reach nerves in the dermis of the skin.

51. The use of any one of claims 42-50, wherein the MN are composed of a biocompatible material.

52. The use of any one of claims 42-51, wherein the MN are composed of a metal.

53. The use of any one of claims 42-51, wherein the MN are composed of at least one dissolving polymer.

54. The use of any one of the preceding claims, wherein during the MSC, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 microneedle (MN) impressions are to be administered, wherein each impression is made in a period of continuous contact between the site and a device that comprises one or more MNs.

55. The use of claim 54, wherein the device is or comprises a stamp that includes the one or more MNs.

56. The use of claim 54, wherein the device is or comprises a roller that includes the one or more MNs.

57. The use of claim 54, wherein the device is or comprises a patch that includes the one or more MNs.

58. The use of any one of claims 54-57, wherein the device comprises a plurality of MNs and MNs of the plurality are arranged in a geometrical pattern.

59. The use of claim 54, wherein during the MSC, a plurality of the impressions is to be administered.

60. The use of any one of claims 59, wherein two or more of the impressions are made on approximately the same site.

61. The use of any one of claims 59, wherein two or more of the impressions are made on overlapping sites.

62. The use of any one of claims 54-59, wherein individual impressions are made on different sites.

63. The use of any one of claims 54-62, wherein the impressions are made by stamping.

64. The use of any one of claims 54-62, wherein the impressions are made by rolling.

65. The use of any one of the preceding claims, wherein the treatment achieves delivery of the large agent into the skin within 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes.

66. The use of any one of the preceding claims, wherein the treatment achieves delivery of the large agent into the skin within 5 to 60 minutes, 5 to 12 minutes, 5 to 15 minutes, or 15 to 30 minutes.

67. The use of any one of the preceding claims, wherein the treatment achieves delivery of the large agent into the skin within 1, 2, 3, 4, 5, or 6 hours.

68. The use of any one of the preceding claims, wherein the medicament is for treating a dermatological disease, disorder, or condition.

69. The use of any one of the preceding claims wherein the subject is suffering from or susceptible to a dermatological disease, disorder, or condition and the treatment achieves improvement of one or more features or symptoms of the dermatological disease, disorder, or condition.

70. The use of claim 68 or 69, wherein the dermatological disease, disorder, or condition is selected from acne, actinic keratosis, body odor, bromhidrosis, burns, chromhidrosis, dermal infection, eczematous dermatitis, excess sebum-producing disorders, facial wrinkles, hair loss, hyperfunctional facial lines, hyperhidrosis, hyperkinetic facial lines, hyperpigmentation disorders, hypopigmentation disorders, keloids, linear morphea, lupus erythematosus, neck lines, platysma bands, psoriasis, Raynaud's Syndrome, rosacea, scleroderma, skin cancer, unsightly facial expressions, unwanted sweating, and/or combinations thereof.

71. The use of any one of the preceding claims, wherein the medicament is for treating or preventing a disease, disorder, or condition selected from acne (*e.g.,* which may be associated with excess sebum production, infection, etc), amyloidosis (*e.g.,* cutaneous amyloidosis), asthma, body odor, burns, cancer (*e.g.,* blood cancer, breast cancer, colon

cancer, lung cancer, skin cancer), disorders associated with sun exposure (*e.g.,* actinic keratosis, sunburn, skin cancer such as melanoma, etc), inflammatory conditions (*e.g.,* chronic obstructive pulmonary disorder, Crohn's disease, sweating disorders (*e.g.,* bromhidrosis, chromhidrosis, dermal infection, discoid lupus, drug-induced lupus, eczematous dermatitis, excess sebum-producing disorders, facial wrinkles, hair loss, hyperfunctional facial lines, hyperhidrosis, hyperkinetic facial lines, hyperpigmentation disorders, hyperplasia (*e.g.,* prostate hyperplasia), hypopigmentation disorders, inflammatory bowel disease, keloids, linear morphea, lupus erythematosus, neck lines, neonatal lupus, osteoarthritis, platysma bands, psoriasis, psoriatic arthritis, pulmonary disorders, Raynaud's Syndrome, rheumatoid arthritis, rosacea, scleroderma, skin cancer, systemic amyloidosis, systemic lupus , ulcerative colitis, unsightly facial expressions, unwanted sweating, dyslipidemia, hypercholesterolemia, infection, *C. difficile* infection, *Staphylococcus* infection, dystonia, headache, pain, arthritis associated pain, rheumatoid arthritis associated pain, psoriatic arthritis associated pain, osteoarthritis associated pain, certain ophthalmologic conditions, certain urologic conditions, neuromuscular disorders, conditions involving muscular spasm and/or contracture, strabismus, hemifacial spasm, tremor, spasticity such as that resulting from multiple sclerosis, retroorbital muscle, neurologic conditions, migraine or other headaches, Alzheimer's Disease, Parkinson's Disease, or stroke, and/or combinations thereof.

72. The use of any one of the preceding claims, wherein the composition is formulated as a lotion, cream, powder, ointment, liniment, gel, or drops.

73. A non-therapeutic method comprising a step of:

administering a plurality of doses of a composition that delivers a large agent having a molecular weight of 100,000 Da or greater to a site on skin of the subject in combination with microneedle skin conditioning (MSC) according to a dosing regimen in which at least two successive doses are separated from one another by a time period of at least one month.

74. The non-therapeutic method of claim 73, wherein the time period is at least two months.

75. The non-therapeutic method of claim 73, wherein the time period is at least four months.

76. The non-therapeutic method of claim 73, wherein the time period is at least six months.

77. The non-therapeutic method of claim 73, wherein the time period is at least eight months.

78. The non-therapeutic method of claim 73, wherein the time period is at least ten months.

79. The non-therapeutic method of claim 73, wherein the time period is at least twelve months.

80. The non-therapeutic method of claim 73, wherein the dosing regimen comprises administering at least three doses, separated by at least first and second time periods, wherein the average time period is at least one month.

81. The non-therapeutic method of claim 80, wherein the average time period is at least two months.

82. The non-therapeutic method of claim 80, wherein the average time period is at least four months.

83. The non-therapeutic method of claim 80, wherein the average time period is at least six months.

84. The non-therapeutic method of claim 80, wherein the average time period is at least eight months.

85. The non-therapeutic method of claim 80, wherein the average time period is at least ten months.

86. The non-therapeutic method of claim 80, wherein the average time period is at least twelve months.

87. The non-therapeutic method of claim 80, wherein each of the time periods is the same.

88. The non-therapeutic method of claim 87, wherein each of the time periods is at least one month.

89. The non-therapeutic method of claim 87, wherein each of the time periods is at least two months.

90. The non-therapeutic method of claim 87, wherein each of the time periods is at least four months.

91. The non-therapeutic method of claim 87, wherein each of the time periods is at least six months.

92. The non-therapeutic method of claim 87, wherein each of the time periods is at least eight months.

93. The non-therapeutic method of claim 87, wherein each of the time periods is at least ten months.

94. The non-therapeutic method of claim 87, wherein each of the time periods is at least twelve months.

95. The non-therapeutic method of any one of the preceding claims, wherein the administering comprises topically applying the composition to the site.

96. The non-therapeutic method of any one of the preceding claims, wherein the composition comprises a nanoemulsion.

97. The non-therapeutic method any one of the preceding claims, wherein the composition comprises a macroemulsion.

98. The non-therapeutic method of any one of the preceding claims, further comprising a step of administering a penetration enhancing agent.

99. The non-therapeutic method of claim 98, wherein the penetration enhancing agent is selected from carrier peptides and co-peptides.

100. The non-therapeutic method of claim 98 or 99, wherein the penetration enhancing agent is selected from a cationic peptide and a positively charged carrier with the sequence RKKRRQRRRG-$(K)_{15}$-GRKKRRQRRR.

101. The non-therapeutic method of any one of the preceding claims, wherein the step of administering comprises performing the MSC prior to administration of the composition to the site.

102. The non-therapeutic method of claim any one of the preceding claims, wherein the step of administering comprises performing the MSC after administration of the composition to the site.

103. The non-therapeutic method of claim any one of the preceding claims, wherein the step of administering comprises performing the MSC concurrently with administration of the composition to the site .

104. The non-therapeutic method of any one of the preceding claims, wherein the large agent is a botulinum toxin.

105. The non-therapeutic method of claim 104, wherein the step of administering is further in combination with a cosmetic agent.

106. The non-therapeutic method of claim 105, wherein the cosmetic agent is selected from the group consisting of anesthetics, collagen, fillers, retinoids, silicone, and combinations thereof.

107. The non-therapeutic method of any one of the preceding claims, wherein the MSC is accomplished with a device comprising at least one microneedle (MN).

108. The non-therapeutic method of claim 107, wherein the device comprises a plurality of MN.

109. The non-therapeutic method of claim 107 or 108, wherein the device is a patch, a roller, a stamp, or a pen.

110. The non-therapeutic method of any one of the preceding claims, wherein the site is a skin surface overlying a muscle or muscle group.

111. The non-therapeutic method of any one of the preceding claims, wherein the site is a skin surface that contains sweat glands.

112. The non-therapeutic method of any one of the preceding claims, wherein the site is a skin surface that contains sebaceous glands.

113. The non-therapeutic method of any one of the preceding claims, wherein the site is a skin surface that contains hair follicles.

114. The non-therapeutic method of any one of claims 107-112, wherein the MN have a length sufficient to project through the stratum corneum of the skin.

115. The non-therapeutic method of any one of claims 107-114, wherein the MN have a length insufficient to reach nerves in the dermis of the skin.

116. The non-therapeutic method of any one of claims 107-115, wherein the MN are composed of a biocompatible material.

117. The non-therapeutic method of any one of claims 107-116, wherein the MN are composed of a metal.

118. The non-therapeutic method of any one of claims 107-116, wherein the MN are composed of at least one dissolving polymer.

119. The non-therapeutic method of any one of the preceding claims, wherein the MSC comprises administration of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 microneedle (MN) impressions, wherein each impression is made in a period of continuous contact between the site and a device that comprises one or more MNs.

120. The non-therapeutic method of claim 119, wherein the device is or comprises a stamp that includes the one or more MNs.

121. The non-therapeutic method of claim 119, wherein the device is or comprises a roller that includes the one or more MNs.

122. The non-therapeutic method of claim 119, wherein the device is or comprises a patch that includes the one or more MNs.

123. The non-therapeutic method of any one of claims 119-122, wherein the device comprises a plurality of MNs and MNs of the plurality are arranged in a geometrical pattern.

124. The non-therapeutic method of claim 119, wherein the MSC comprises administration of a plurality of the impressions.

125. The non-therapeutic method of any one of claims 124, wherein two or more of the impressions are made on approximately the same site.

126. The non-therapeutic method of any one of claims 124, wherein two or more of the impressions are made on overlapping sites.

127. The non-therapeutic method of any one of claims 119-124, wherein individual impressions are made on different sites.

128. The non-therapeutic method of any one of claims 119-127, wherein the impressions are made by stamping.

129. The non-therapeutic method of any one of claims 119-127, wherein the impressions are made by rolling.

130. The non-therapeutic method of any one of the preceding claims, wherein the step of administering achieves delivery of the large agent into the skin within 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes.

131. The non-therapeutic method of any one of the preceding claims, wherein the step of administering achieves delivery of the large agent into the skin within 5 to 60 minutes, 5 to 12 minutes, 5 to 15 minutes, or 15 to 30 minutes.

132. The non-therapeutic method of any one of the preceding claims, wherein the step of administering achieves delivery of the large agent into the skin within 1, 2, 3, 4, 5, or 6 hours.

133. The non-therapeutic method of any one of the preceding claims, wherein the composition is formulated as a lotion, cream, powder, ointment, liniment, gel, or drops.